Table 3. Duration of DAA according to the presence of ribavirin (RBV), decompensated cirrhosis, genotype and DAA regimen.
| Duration of DAA, weeks | |||||
|---|---|---|---|---|---|
| Median (IQR) | p-value | < = 12 n (%) | >12 n (%) | p-value | |
| Use of Ribavirine | 0.431 | 0.932 | |||
| No | 13.5 (12.0, 24.0) | 134 (37.2) | 226 (62.8) | ||
| Yes | 12.7 (12.0, 24.0) | 155 (37.7) | 256 (62.3) | ||
| HCV genotype | < .001 | < .001 | |||
| 1 | 12.3 (12.0, 23.9) | 159 (44.7) | 197 (55.3) | ||
| 2 | 16.0 (12.0, 24.0) | 3 (33.3) | 6 (66.7) | ||
| 3 | 24.0 (23.7, 24.1) | 15 (12.7) | 103 (87.3) | ||
| 4 | 12.0 (12.0, 23.4) | 54 (52.9) | 48 (47.1) | ||
| Other | 12.0 (12.0, 22.0) | 3 (60.0) | 2 (40.0) | ||
| 1,2,4,other | 12.1 (12.0, 23.9) | 219 (46.4) | 253 (53.6) | ||
| Decompensated cirrhosis | < .001 | < .001 | |||
| No | 12.3 (12.0, 24.0) | 224 (42.1) | 308 (57.9) | ||
| Yes | 23.9 (12.6, 24.3) | 10 (17.2) | 48 (82.8) | ||
| Regimen | < .001 | < .001 | |||
| 2D+RBV | 12.2 (12.0, 24.0) | 8 (40.0%) | 12 (60.0%) | ||
| 3D(±RBV) | 12.1 (12.0, 13.1) | 63 (48.8) | 66 (51.2) | ||
| DCL+SOF(±RBV) | 24.0 (23.4, 24.3) | 15 (13.2) | 99 (86.8) | ||
| LDV/SOF(±RBV) | 12.0 (12.0, 24.0) | 73 (50.3) | 72 (49.7) | ||
| SOF+PR | 12.4 (12.3, 14.6) | 3 (16.7) | 15 (83.3) | ||
| SOF+RBV | 24.0 (23.7, 24.4) | 5 (11.6) | 38 (88.4) | ||
| SOF+SIM(±RBV) | 12.0 (12.0, 12.1) | 65 (72.2) | 25 (27.8) | ||
| TLP+PR | 48.0 (26.9, 49.0) | 1 (6.7) | 14 (93.3) | ||
p-value: Wilcoxon or Kruskal-Wallis test or Chi-square test as appropriate.